Degradable sclera fixing ring carrying gene editing carrier

Abstract

The invention discloses a degradable sclera fixing ring carrying a gene editing carrier. The degradable sclera fixing ring comprises a fixing ring, a glass slide and a baffle ring, a plurality of uniformly distributed grooves are formed in the fixing ring, a glass slide is carried in the fixing ring, and the baffle ring is located above the glass slide. Compared with the prior art, the preparation method has the advantages that the PLGA microspheres are embedded in the microspheres to wrap the gene carrier, the gene carrier is dispersed in the pores of the matrix, the surface of the matrix is modified by the cationic polymer through electrostatic adsorption, negatively charged nucleic acid and a hydrogel slow-release layer are adsorbed, and the hydrogel slow-release layer is a thermo-sensitive hydrogel loading carrier, so that on-demand release is realized.

Description

Technical Field

[0001] The present invention relates to the technical field of fixing rings, specifically a degradable scleral fixing ring carrying a gene editing vector. Background Art

[0002] Treatment dilemmas of ophthalmic diseases: Hereditary retinopathies such as Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), etc. For traditional gene therapy, repeated intravitreal injections are required, with low patient compliance and high infection risk. Degenerative ophthalmic diseases such as glaucoma optic atrophy, age-related macular degeneration (AMD). Existing drugs (such as anti-VEGF) need to be injected monthly, with a heavy long-term treatment burden. Structural ophthalmic diseases: After posterior scleral reinforcement for high myopia and after retinal detachment surgery, non-degradable materials (such as silicone rings) need to be implanted, resulting in problems such as foreign body rejection and secondary surgery for removal.

[0003] Limitations of existing treatment methods: Low gene delivery efficiency: Virus vectors (such as AAV) are limited in diffusion within the eye and it is difficult to target deep retinal cells. Lack of sustained treatment: Traditional injected drugs have a short half-life and cannot maintain long-term efficacy. Mechanical and treatment functions are separated: Existing scleral fixing rings only provide support and have no treatment function, requiring additional intervention. Summary of the Invention

[0004] The technical problem to be solved by the present invention is to overcome the above technical defects

[0005] To solve the above problems, the technical solution of the present invention is: A degradable scleral fixing ring carrying a gene editing vector, including a fixing ring, a slide, and a retaining ring;

[0006] A number of evenly distributed grooves are provided on the fixing ring, a slide is carried inside the fixing ring, and the retaining ring is located above the slide.

[0007] Further, the retaining ring is a convex structure.

[0008] Further, the retaining ring is made of PLGA: poly(lactic-co-glycolic acid) material, the degradation time is controllable within 3 - 12 months, and the PCL retaining ring 3 is made of polycaprolactone, with a long degradation period of 1 - 2 years and good flexibility, suitable for long-term support.

[0009] The advantages of the present invention compared with the existing technology are as follows:

[0010] The present invention is provided with a fixing ring, a slide, and a retaining ring. By using the convex structure of the retaining ring, it can play a role in targeting deep retinal cells. Traditional injected drugs have a short half-life, and during the treatment process, additional intervention can be more obvious, so as to observe retinal cells. Brief Description of the Drawings

[0011] Figure 1 This is a perspective view of the degradable scleral fixation ring carrying the gene editing vector of the present invention.

[0012] Figure 2 This is a side view of the degradable scleral fixation ring carrying the gene editing vector of the present invention.

[0013] As shown in the figure: 1. Fixation ring; 2. Slide; 3. Retaining ring; 4. Groove. Detailed implementation manners

[0014] The following will further illustrate the detailed implementation manners of the present invention with reference to the accompanying drawings. The same components are denoted by the same reference numerals.

[0015] It should be noted that the terms "front", "rear", "left", "right", "upper" and "lower" used in the following description refer to the directions in the drawings, and the terms "inner" and "outer" respectively refer to the directions towards or away from the geometric center of a specific component.

[0016] To make the content of the present invention more clearly understood, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention.

[0017] As Figures 1 to 2 shown, the degradable scleral fixation ring carrying the gene editing vector includes a fixation ring 1, a slide 2 and a retaining ring 3; a plurality of uniformly distributed grooves 4 are provided on the fixation ring 1, the slide 2 is carried inside the fixation ring 1, the retaining ring 3 is located above the slide 2, the retaining ring 3 is a convex structure, the retaining ring 3 is made of PLGA: poly(lactic-co-glycolic acid) material, the degradation time is controllable for 3 - 12 months, and the PCL retaining ring 3 is made of polycaprolactone, with a long degradation period of 1 - 2 years and good flexibility, suitable for long-term support.

[0018] In specific use, the anesthesia method adopts local anesthesia (peribulbar / retrobulbar anesthesia) or general anesthesia (for children / special patients).

[0019] Conjunctival incision: Make a 5 - 8 mm arc incision in the superotemporal or nasal quadrant, and separate the Tenon's capsule to expose the sclera.

[0020] Scleral ring implantation

[0021] Positioning and marking: Use OCT or fluorescence imaging (such as Cy5.5 labeling) to confirm that the ring body is placed on the posterior sclera at the equator.

[0022] Fixing method: Absorbable suture anchoring: Use 6 - 0 Vicryl suture to suture the ring body to the scleral surface (4 - 6 fixation points).

[0023] Biological glue adhesion: fibrin glue-assisted fixation to reduce suture friction (applicable to patients with thin sclera).

[0024] Closure and inspection of layered suture: reposition the Tenon's capsule and conjunctiva (continuous suture with 8-0 nylon thread).

[0025] The above describes the present invention and its implementation manners. Such description is not restrictive. What is shown in the drawings is only one of the implementation manners of the present invention, and the actual structure is not limited thereto. Generally speaking, if those of ordinary skill in the art are inspired by it and without departing from the purpose of the present invention creation, and design similar structural manners and embodiments to this technical solution without creative efforts, they shall fall within the protection scope of the present invention.

Claims

1. A degradable scleral fixation ring carrying a gene editing vector, characterized in that: It includes a fixing ring (1), a glass slide (2), and a retaining ring (3); The fixing ring (1) is provided with a number of evenly distributed grooves (4). The glass slide (2) is carried inside the fixing ring (1), and the retaining ring (3) is located above the glass slide (2).

2. The degradable scleral fixation ring carrying the gene editing vector according to claim 1, wherein: The retaining ring (3) is a convex structure.

3. The degradable scleral fixation ring carrying the gene editing vector according to claim 1, wherein: The retaining ring (3) is made of PLGA: poly (lactic-co-glycolic acid) material, and the degradation time can be controlled for 3 - 12 months. The PCL retaining ring (3) is made of polycaprolactone, has a long degradation period of 1 - 2 years, and good flexibility, suitable for long-term support.

Images